SOTIO begins Phase III trial of DCVAC/PCa to treat prostate cancer
The randomized, double blind, multicenter, parallel-group Phase III trial is designed to evaluate the safety and efficacy of DCVAC/PCa as an add-on therapy to 1st line standard of
The randomized, double blind, multicenter, parallel-group Phase III trial is designed to evaluate the safety and efficacy of DCVAC/PCa as an add-on therapy to 1st line standard of
The exclusive license grants GCA Therapeutics the right to clinically develop and commercialize Leptin Products in China, exclusive of Hong Kong, and Taiwan. The company said that a
The company said that EscharEx is based on its patented proteolytic enzyme technology. About 72 patients are expected to be enrolled in the prospective, randomized, controlled, multicenter Phase
The loan will support the development of LP2, the first peptide-based drug , for treatment of Idiopathic Pulmonary Fibrosis. LP2 is an innovative lanthipeptide used to activate the
The deal, which is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development, is focused on identifying, validating, and screening novel
PML is a rare side effect of small molecule and antibody drugs given to patients with autoimmune diseases such as arthritis and multiple sclerosis (MS). It also occurs
ClinPay solution of Clinverse automates sponsor payments to clinical vendors, investigators, and other parties across the entire financial lifecycle of a clinical trial, reducing workload and costs while
DSM Fine Chemicals is a business unit of the newly formed DPx Holding which also owns Patheon Pharma Services and Banner Life Sciences. Relypsa senior vice president of
Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound and it functions by binding to the nuclear export protein XPO1 (CRM1), leading to the accumulation
The company said that ABI-009 leverages the same technology of the nab platform that is behind the success of ABRAXANE (paclitaxel protein-bound particles for injectable suspension). Under the